UnitedHealth insiders scooped up shares after the insurer’s stock swooned to a five-year low last week amid mounting federal ...

At that time point 92% of patients who received Delytact were still alive, considerably more than would be expected for this group of patients, who typically have a one-year survival rate of only ...